impress fourth-quart dramat rais guidanc
maintain outperform catalyst-rich
friday januari market open report fourth quarter full
year financi result exhibit beat expect top bottom
line rais ep growth guidanc larg due improv
oper margin benefit tax reform biggest surpris quarter
strong mavyret launch exit hcv market share less
two quarter market continu forecast peak market share
mavyret franchis reach equilibrium gilead outperform
hcv franchis continu project top- bottom-lin compound-annual-growth-rate
respect beyond humira revenu
start declin project top- bottom-lin compound-annual-growth-rate respect howev
note project includ current market product late stage pipelin
candid believ current earlier stage asset start contribut
growth beyond
threat humira biosimilar entri held bay continu look numer
near-term pivot readout new product launch label expans sustain share
price out-performance continu drive growth beyond loss humira exclus
earli data pivot studi triniti rova-t third-lin later small-
cell lung cancer sclc expect second quarter potenti product launch
follow around year-end elagolix expect approv endometriosi
associ pain first half bleed due uterin fibroid approv
risankizumab psoriasi upadacitinib rheumatoid arthriti anticip
label expans new exist product expect throughout
next five seven year key pipelin event watch rova-t triniti
data upadacitinib safeti profil opinion believ risankizumab elagolix
repres littl data regulatori risk
maintain outperform rate increas fair valu estim share
assum price-to-earnings multipl percentil among pharma
peer even sizabl appreci share recent month stock
continu trade discount pharma biotech peer despit fact abbvi
current repres highest growth rate pharma peer group new fair valu
estim put among top term price-to-earnings multipl believ
growth prospect well strong pipelin deserv premium
return equiti ttm
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
friday januari market open report fourth quarter full year financi result
exhibit beat expect top bottom line rais ep growth guidanc
revenu quarter billion beat estim billion consensu
billion world-wide humira revenu billion also beat estim billion consensu
billion imbruvica revenu record million lower estim million
consensu million hcv franchis sale million includ million come mavyret beat
estim million consensu million bottom line non-gaap ep
consensu estim full-year non-gaap ep versu estim consensu
complet varianc analysi expect consensu actual result summar exhibit manag
issu guidanc non-gaap ep announc potenti dividend increas share
buyback year pend board approv new ep estim previou estim
remain guidanc also rais ep estim
maintain outperform rate increas fair valu estim share base
updat guidanc detail updat pipelin project describ detail herein
exhibit believ flurri pivot data readout throughout continu support
out-performance share note despit recent share appreci result coheru
ipr denial market perform settlement numer posit pipelin data readout
still trade discount large-cap biotech pharma compani exhibit note pharmaceut
peer group highest ep growth rate believ deserv valu premium updat
valuat took averag time non-gaap ep estim time estim time
estim multipl chosen percentil compar biotech pharmaceut
multipl given year use formula arriv fair valu estim share compound-annual-growth-rate
describ believ gradual share could garner higher-than-averag multipl go forward
manag issu guidanc non-gaap ep variou oper metric call roughli
bottom-lin growth midpoint driven expect stronger oper perform well
posit impact passag tax reform act compani project non-gaap ep
increas estim guidanc achiev larg
lower oper expens expect tax rate
benefit tax reform compani guid non-gaap tax rate grow next
five year due increas domest incom invest intend invest billion capit project
unit state next five year acceler pension fund million make one-tim
charit donat million
full-year net revenu billion repres growth previou year top three
product humira sale grew quarter-over-quart imbruvica grew sequenti hcv franchis
sale increas bolster rapid mavyret uptak non-gaap ep came
guid rang beat estim consensu humira continu
demonstr strong posit market despit new competit fourth quarter sale maintain
double-digit year-over-year growth rate consecut quarter exhibit world-wide humira growth
year-over-year driven increas unit state increas intern exhibit humira
account adjust sale year imbruvica revenu grew year
includ increas sale increas intern profit share expect imbruvica
continu domin second-lin chronic lymphocyt leukemia cll set current hold
market well continu expans frontlin cll recent approv indic margin zone lymphoma
chronic graft-versus-host diseas hcv franchis sale present pleasant surpris fourth quarter first
full quarter mavyret sale sinc approv total million roughli million came mavyret
repres quarter-over-quart growth rate
increas sale estim hcv franchis billion billion line
guidanc quarter-over-quart basi hcv revenu grew driven rapid uptak mavyret manag note
end mavyret penetr hcv market current contract access
cover patient believ impress given short time market due mavyret simpl algorithm
competit profil forecast mavyret achiev world-wide matur market share could
conserv continu see hcv franchis led mavyret major growth driver beyond
reach peak sale billion
project top- bottom-lin compound-annual-growth-rate respect end
beyond humira revenu start declin dramat project top- bottom-
line compound-annual-growth-rate respect current late-stag pipelin could sustain growth
humira declin new launch beyond outsid current late-stag pipelin could lead continu growth
view beyond top line start declin current model note
project includ current product late stage pipelin exhibit earlier stage pipelin product could increas
compound-annual-growth-rate maintain growth beyond
threat humira biosimilar entri bay look numer near-term new product launch
label expans sustain share price out-performance continu drive growth beyond loss humira
exclus earli opinion higher risk pipelin event includ rova-t pivot readout
upadacitinib safeti profil reveal second quarter expect top-lin data pivot studi triniti
rova-t third-lin later small-cel lung cancer sclc potenti product launch follow around end
triniti repeat efficaci observ phase i/ii studi believ rova-t like garner approv set
current treatment option howev question surround safeti posit competit
landscap could pose certain risk surround eventu approv use market detail rova-t
sclc field pleas refer note small-cel lung cancer recap call dr charl rudin state-of-the-industri
analysi publish octob
earli also expect top-lin result select-earli select-compar fourth fifth trial
phase program investig inhibitor upadacitinib rheumatoid arthriti ra posit result could
trigger regulatori file later year howev also note three phase studi program
alreadi read imbal thromboembol event occur ratio upadacitinib arm
versu placebo arm await result next two studi evalu safeti signal
potenti risk pose upadacitinib develop approv detail upadacitinib safeti concern
surround jak inhibitor class pleas refer note publish decemb titl state jak inhibitor
class year-end safeti question take center stage
elagolix expect approv endometriosis-associ pain first half bleed due
uterin fibroid approv risankizumab psoriasi anticip label expans expect
next five seven year view event lower risk rova-t upadacitinib discuss
risk includ earlier project biosimilar entri humira failur market product fulfil
expect failur key pipelin program commerci success polit risk busi
humira hcv imbruvica total sg acquir in-process research total oper interest expens net foreign exchang incom expens pre-tax incom tax tax non- net intang asset separ mileston acquir acquisit relat intang asset impairment- tax reform repatri tax- impact relat tax law change- tax audit settlement- legal reserves- restructuring- chang fair valu conting transact dividend per common averag share outstand weight averag share outstand compani report william blair inc incom estimatespreadvarianceq/q growthy/i growthcon estimate humira oper net compani report william blair estimatescurr quarterexhibit inc current quarter varianc analysi dollar billion except ep william blair
record record record record record exclud top record abbviesourc william blair co estimatesexhibit inc estim product revenuesbiotechnolog consult last page report disclosur price factset william blair co estimatesabbvi inc exhibit william blair
compani reportsexhibit inc humira world-wide y/i y/i growth compani report william blair estimatesexhibit inc humira y/i growth y/i growtheu y/i growthww y/i growth william blair
sourc compani report william blair estimatesabbvi inc anticip upcom drug approvalsexhibit import disclosur
